The Window When Environment Matters Most
Research has shown that exposure to certain industrial chemicals can begin before birth. Understanding why the earliest developmental windows are uniquely sensitive is one of the strongest arguments for practical, prioritised exposure reduction.
1. The Window of Sensitivity
In biology, timing is everything. While exposure to hormone disruptors matters throughout life, the developmental windows — preconception, pregnancy, and early childhood — are uniquely sensitive. During these periods, hormones help guide brain development, reproductive development, metabolism, immune programming, and growth. Small disruptions during these windows may have outsized effects compared with the same exposure later in life. At the same time, the developing foetus has only limited capacity to process and eliminate certain toxicants, making early-life exposure a particularly important focus for prevention.
2. The Cord Blood Evidence
One of the most significant shifts in environmental health science was the recognition that chemical exposure does not begin in adulthood. Research over the last several decades has shown that a range of industrial chemicals can be detected during pregnancy and, in some cases, in umbilical cord blood at birth. Independent research has detected substances such as PFAS, flame retardants, mercury, pesticides, and certain plastic-related compounds in maternal and cord blood samples — confirming that the placenta is not an absolute barrier against many modern synthetic contaminants. It is more accurately described as a filter than a shield.
This changed the public conversation in a profound way: the issue was no longer limited to what adults encounter over a lifetime, but also what developing babies may be exposed to during their earliest and most vulnerable stage of life.
Exposure to hormone-disrupting chemicals is not only an adult issue. Research suggests that for some chemicals, exposure may begin before birth — making early-life prevention one of the strongest arguments for practical endocrine resilience.
3. What This Means in Practice
Rather than promoting alarm, this science justifies why the kitchen and bathroom are the highest-leverage places for parents and those trying to conceive to begin. Reducing repeated exposure to common EDCs like bisphenols and phthalates is a practical, evidence-supported goal. The goal cannot be total avoidance — it must be prioritised risk reduction: lowering the most meaningful exposures where possible, supporting the body’s natural elimination systems through nutrition and daily habits, and paying special attention to sensitive life stages.
4. Case Study: BPA in Baby Bottles
The debate over bisphenol A (BPA) in baby bottles is one of the most thoroughly documented examples of the gap between emerging science and regulatory response in modern public health history. It is also a story about how independent science, consumer pressure, and market forces can move faster than official regulation — and about why the removal of a single chemical does not resolve the underlying problem.
Background: What Is BPA and Why Was It in Baby Bottles?
BPA was first synthesised in 1891. Its oestrogenic properties were identified in the 1930s. Despite this, BPA became one of the most widely produced industrial chemicals in the world, used primarily to make polycarbonate plastic and epoxy resins. Polycarbonate plastic — hard, clear, and durable — became the dominant material for baby bottles and sippy cups from the 1950s onwards.
The critical exposure concern: BPA can leach from polycarbonate plastic into liquids — and leaching increases significantly when the plastic is heated. Parents routinely heated baby bottles in microwaves or boiling water. Infants were therefore receiving BPA-contaminated milk or formula at the most developmentally vulnerable period of their lives.
Early low-dose research raises alarm
Researcher Frederick vom Saal published studies showing that very low doses of BPA could have biological effects in mice — specifically on prostate development. This was among the first serious low-dose BPA research and directly challenged the assumption that BPA was safe at typical human exposure levels.
Why it matters: Vom Saal’s research introduced the concept of non-monotonic dose-response to the BPA debate — the idea that lower doses can sometimes produce greater effects than higher doses for hormone-active substances.
CDC biomonitoring: BPA found in over 90% of Americans
The US CDC published NHANES data showing that BPA was detectable in the urine of over 90% of the US population tested. Baby bottles were immediately identified as a significant exposure source, particularly because heating polycarbonate bottles was shown to substantially increase BPA leaching.
Why it matters: This data transformed BPA from a theoretical concern to a confirmed, widespread human exposure reality. It made the baby bottle issue impossible to dismiss.
The debate goes mainstream — 38 scientists challenge the FDA
The National Toxicology Program expressed concern about low-dose BPA effects, particularly for infants and foetuses. In the same year, 38 leading BPA researchers signed the Chapel Hill Consensus Statement, concluding that average BPA levels in people were above those shown to cause harm in animal studies.
Why it matters: The Chapel Hill Consensus Statement was a pivotal moment. It represented a direct, public challenge to the regulatory consensus by a large group of independent scientists.
Canada acts first — the FDA holds its position
The US National Toxicology Program released a draft report expressing “some concern” about BPA effects on the brain, behaviour, and prostate gland in foetuses, infants, and children. In the same month, Canada declared BPA a toxic substance and announced a ban on BPA in baby bottles — becoming the first country to take formal regulatory action.
Why it matters: Canada’s action put enormous pressure on US regulators and retailers. It demonstrated that regulatory action was possible — and that the FDA’s position was not the only credible institutional response.
The market moves faster than the regulator
Major US retailers including Walmart, Toys R Us, and CVS announced they would pull BPA-containing baby bottles and sippy cups from shelves — acting entirely ahead of any US regulatory decision. Major manufacturers announced they would stop producing BPA-containing baby bottles for the US market.
Why it matters: This was a landmark moment: the market moved faster than the regulator. Consumer pressure, media coverage, and competitive dynamics drove manufacturers and retailers to act without waiting for the FDA.
FDA reverses position
The FDA reversed its earlier position and stated it had “some concern” about BPA’s effects on the brain, behaviour, and prostate gland in foetuses, infants, and young children. The FDA stopped short of banning BPA outright but began supporting efforts to find alternatives in food contact materials.
Why it matters: The FDA’s reversal came approximately two years after the market had already moved. By 2010, BPA-free baby bottles were already the norm in US retail.
FDA formally bans BPA from baby bottles and sippy cups
The FDA officially banned BPA from baby bottles and sippy cups — but did so in response to a petition from the American Chemistry Council, which argued the ban was appropriate because manufacturers had already voluntarily stopped using BPA in these products.
Why it matters: The formal ban arrived approximately four years after the market had already eliminated BPA from baby bottles. It nonetheless established an important regulatory precedent.
5. The substitution problem: “BPA-free” is not the full answer
The removal of BPA from baby bottles did not end the story. Manufacturers replaced BPA with structurally similar bisphenol compounds — most commonly BPS and BPF — which were marketed under the “BPA-free” label. Subsequent research has shown that BPS and BPF also have oestrogenic activity and may produce similar endocrine-disrupting effects to BPA.
This is one of the most important lessons of the BPA baby bottle story: removing a named chemical from a product category does not resolve the underlying problem if the replacement chemicals share the same mechanism of concern. It is a lesson that applies across the entire landscape of endocrine-disrupting chemicals — and it is one of the reasons Endocrine Resilience focuses on chemical families and exposure routes rather than individual named chemicals.
For clinicians and health professionals, the Clinical Portal provides deeper evidence summaries and clinical tools.
Educational content only. This material is not a substitute for individualised medical advice, diagnosis, or treatment.